ZGPAT (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:84619, GPATC6, GPATCH6, HGNC:15948, KIAA1847, MIM:619577, NM_001083113, NM_001195653, NM_001195654, NM_032527, NM_181484, NM_181485, NP_001076582, NP_001182582, NP_001182583, NP_115916, NP_852150, ZC3H9, ZC3HDC9, ZGPAT, ZIP, zinc finger CCCH-type and G-patch domain containing

Omim:OMIM:619577

Id:ENSG00000197114

Hgnc:HGNC:15948

Entrez:84619

Ensembl:ENSG00000197114

Description:zinc finger CCCH-type and G-patch domain containing

Enables DNA-binding transcription repressor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Involved in negative regulation of epidermal growth factor-activated receptor activity and negative regulation of transcription by RNA polymerase II. Located in nucleoplasm and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ZGPAT's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ZGPAT.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ZGPAT.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ZGPAT.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ZGPAT.

Results found

Linked to

	Label	Description
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE217552 fisetin 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE241036 0 V 1 ETHANOL MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE130396 8 V 6 NERATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	T62-Spleen Consensus Gene Set (Entity type)	A Gene Set from MoTrPAC
	GSE220520 5 V 4 ETHANOL MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE217552 3 V 2 FISETIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE92965 0 V 1 TAMOXIFEN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE62843,GSE64371 4 V 3 FURAN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE217552 fisetin 3 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE241036 0 V 1 ETHANOL MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE130396 8 V 6 NERATINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

T62-Spleen Consensus

Gene Set (Entity type)

A Gene Set from MoTrPAC

GSE220520 5 V 4 ETHANOL MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE217552 3 V 2 FISETIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE92965 0 V 1 TAMOXIFEN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE62843,GSE64371 4 V 3 FURAN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.